Table 1

Clinical details of the patients with rheumatoid arthritis and healthy donors recruited to the study

Rheumatoid arthritis
(n=72)
Healthy donors
(n=29)
P value
Clinical parameters
Female/male, n/n46/2617/120.096
Age, years54.0±11.750.2±10.20.078
Evolution time, years7.4±7.5
DAS283.2±1.4
Rheumatoid factor positivity, n/n (%)47/72 (65)0/29 (0)<0.001*
Anti-CCPs antibodies positivity, n/n (%)61/72 (85)1/29 (3)<0.001*
Pathological CIMT, n/n (%)27/72 (38)0/29 (0)
Obesity, n/n (%)12/72 (17)3/29 (12)0.846
Diabetes mellitus, n/n (%)0/72 (0)0/29 (0)
BMI (kg/m2)26.3±5.124.2±3.70.115
Hypertension, n/n (%)18/72 (25)0/29 (0)
Menopause, n/n (%)28/72 (40)0/29 (0)
Smoker, n/n (%)18/72 (25)5/29 (19)0.500
Radiological involvement, n/n (%)28/72 (38)0/29 (0)
Laboratory parameters
Total cholesterol, mg/dL202.6±39.3193.0±41.00.155
HDL-cholesterol, mg/dL54.24±17.954.0±22.00.348
LDL-cholesterol, mg/dL126.8±33.0127.0±31.00.607
Apolipoprotein A, mg/dL151.2±31.3147.1±28.10.553
Apolipoprotein B, mg/dL84.1±19.584.9±26.90.537
Triglycerides, mg/dL106.3±52.273.0±29.00.101
CRP, mg/dL10.4±14.80.8±0.975<0.001*
ESR, mm/hour11.3±14.67.3±4.70.070
Treatments
Corticosteroids, n/n (%)42/72 (58)0/29 (0)
Antimalarials, n/n (%)19/72 (26)0/29 (0)
NSAIDs, n/n (%)58/72 (80)0/29 (0)
Methotrexate, n/n (%)41/72 (57)0/29 (0)
Leflunomide, n/n (%)18/72 (25)0/29 (0)
Vitamin D, n/n (%)15/72 (22)0/29 (0)
  • *Denotes significant changes, P<0,001.

  • Anti-CCP, anti cyclic citrullinated protein; BMI, Body Mass Index; CIMT, carotid intima media thickness; CRP, C-reactive protein; DAS28, Disease activity score-28; ESR, erythrocyte sedimentation rate; HDL, high density lipoproteins; LDL, low density lipoproteins; NSAIDs, non-steroidal anti-inflammatory drugs.